ALPHARETTA, Ga., Dec. 19, 2023 /PRNewswire/ -- Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii® (methylphenidate hydrochloride extended-release tablets). Relexxii is a once-daily central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and in pediatric patients 6 years of age and older.1 With the introduction of Relexxii, patients and health care professionals will have an additional branded ADHD treatment option from which to choose.
Enforcement Report - Week of March 02, 2022
Ascent Pharms' Generic Methylphenidate Hydrochloride gets Approval in the U.S.
The company’s product is generic version of Janssen Pharmaceuticals’ Concerta tablets, Dr Reddy’s Laboratories said in a statement. The company’s product is generic version of Janssen Pharmaceuticals’ Concerta tablets, Dr Reddy’s Laboratories said in a statement.
Sun Pharm`s Generic Methylphenidate Hydrochloride Receives Approval In US
Prinston Inc Generic Methylphenidate Hydrochloride Receives Approval in US
Quagen`s Generic Methylphenidate Hydrochloride Receives Approval in US
RESEARCH TRIANGLE PARK, N.C. — Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it is presenting a poster featuring a post-hoc analysis of a Phase 3 trial of children with ADHD comparing the optimized dose JORNAY PM® (Methylphenidate HCl) to the study participants’ prior stable stimulant doses.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced it is presenting two posters featuring new analyses of its novel delayed-release and extended-release methylphenidate formulation. These analyses demonstrate that the uniphasic drug delivery system and site of absorption produce a gradual absorption and protracted elimination phase resulting in attenuated peak drug concentration levels across the dosing range and may lead to a dose-dependent duration of effect. The posters are available for download at the Virtual Scientific Poster Session of the Neuroscience Education Institute (“NEI”). This initiative was coordinated in response to the COVID-19 pandemic and is designed to fill the void in the presentation and dissemination of emerging science historically presented during live meetings. The posters will be accessible to NEI’s 65,700 members and subscribers at http://nei.global/vsp.
Patrin Pharma’s Generic Methylphenidate Hydrochloride Receives Approval In US